M
Middle East Pharmaceutical Industries Company SJSC
SAU:4016
Middle East Pharmaceutical Industries Company SJSC
SAU:4016
Price:
121.2
SAR
1.68%
Market Closed
Market Cap:
2.4B
SAR
Balance Sheet
Balance Sheet Decomposition
Middle East Pharmaceutical Industries Company SJSC
Middle East Pharmaceutical Industries Company SJSC
| Current Assets | 323.8m |
| Cash & Short-Term Investments | 13.8m |
| Receivables | 175.8m |
| Other Current Assets | 134.3m |
| Non-Current Assets | 170.2m |
| PP&E | 120.4m |
| Intangibles | 49.9m |
Balance Sheet
Middle East Pharmaceutical Industries Company SJSC
Middle East Pharmaceutical Industries Company SJSC
Currency: SAR
Millions
Annual
| Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|
| Assets | |||||
| Cash & Cash Equivalents |
16
|
19
|
24
|
15
|
|
| Cash |
16
|
19
|
24
|
15
|
|
| Total Receivables |
113
|
167
|
157
|
165
|
|
| Accounts Receivables |
110
|
164
|
152
|
156
|
|
| Other Receivables |
3
|
3
|
6
|
10
|
|
| Inventory |
83
|
74
|
100
|
87
|
|
| Other Current Assets |
14
|
9
|
10
|
10
|
|
| Total Current Assets |
225
|
269
|
291
|
278
|
|
| PP&E Net |
95
|
103
|
106
|
119
|
|
| PP&E Gross |
95
|
103
|
106
|
119
|
|
| Accumulated Depreciation |
53
|
60
|
65
|
73
|
|
| Intangible Assets |
28
|
34
|
41
|
47
|
|
| Long-Term Investments |
23
|
10
|
4
|
1
|
|
| Total Assets |
371
N/A
|
417
+12%
|
442
+6%
|
445
+1%
|
|
| Liabilities | |||||
| Accounts Payable |
26
|
33
|
38
|
28
|
|
| Accrued Liabilities |
10
|
8
|
10
|
17
|
|
| Short-Term Debt |
42
|
66
|
69
|
50
|
|
| Current Portion of Long-Term Debt |
0
|
5
|
6
|
6
|
|
| Other Current Liabilities |
6
|
6
|
8
|
12
|
|
| Total Current Liabilities |
85
|
117
|
132
|
113
|
|
| Long-Term Debt |
21
|
16
|
10
|
3
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
|
| Other Liabilities |
13
|
17
|
21
|
22
|
|
| Total Liabilities |
118
N/A
|
150
+27%
|
162
+8%
|
138
-15%
|
|
| Equity | |||||
| Common Stock |
60
|
60
|
200
|
200
|
|
| Retained Earnings |
192
|
207
|
80
|
106
|
|
| Total Equity |
252
N/A
|
267
+6%
|
280
+5%
|
306
+9%
|
|
| Total Liabilities & Equity |
371
N/A
|
417
+12%
|
442
+6%
|
445
+1%
|
|
| Shares Outstanding | |||||
| Common Shares Outstanding |
20
|
20
|
20
|
20
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
